Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference
Relmada Therapeutics (Nasdaq: RLMD) will present at the Leerink Partners Global Healthcare Conference in Miami on March 10, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Relmada Therapeutics (Nasdaq: RLMD) will present at the Leerink Partners Global Healthcare Conference in Miami on March 10, 2026. CEO Sergio Traversa and CFO Maged Shenouda will participate in a fireside chat at 8:40 AM ET, with management available for one-on-one investor meetings.
The live webcast is accessible via the company Events page and an archived replay will be available for 90 days after the event.
Details
News Market Reaction – RLMD
On Mar 10, the first trading day after this news, RLMD closed 7.67% below the previous close.
Data tracked by StockTitan Argus for the Mar 10 session.
Key Figures
- Conference dates
- March 8-11, 2026
- Leerink Partners Global Healthcare Conference schedule
- Presentation date
- March 10, 2026
- Relmada fireside chat date at conference
- Presentation time
- 8:40 AM ET
- Scheduled time for conference fireside chat
- Replay availability
- 90 days
- Archived webcast access period after event
Historical Context
-
FDA written feedback supporting registrational Phase 3 design for NDV-01.
-
Phase 2 NDV-01 data with favorable safety and 92% complete response rate.
-
Q3 2025 results plus strong NDV-01 data and Phase 3 pathway clarity.
-
Announcement of upcoming Q3 2025 results call and webcast logistics.
-
Pricing of $100M underwritten stock and pre-funded warrant offering.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CORAL GABLES, Fla., March 09, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in the Leerink Partners Global Healthcare Conference being held in Miami, Florida, from March 8-11, 2026.
Leerink Partners Global Healthcare Conference Details
Format: Fireside Chat
Date Tuesday, March 10, 2026
Time: 8:40 AM ET
Webcast: Click Here
Management will also be available for one-one-one investor meetings during the conference. Please contact your Leerink Partners representative to schedule a meeting.
The webcast can also be accessed on the Events page the Investors section of the Relmada website at https://www.relmada.com/for-investors/ir-calendar An archived replay will be available for 90 days following the conclusion of the event.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through mid-stage clinical development with the potential to address significant unmet needs.
For more information, visit www.relmada.com
Investor Contact:
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com
Media Inquiries:
Corporate Communications
media@relmada.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.